Skye Bioscience, Inc. (SKYE)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.69 on 9 Oct 2026

0 buys18 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$55.92M

Free cash flow

$43.07M

Return on equity

-279.3%

Return on capital

-229.0%

Debt to equity

0.00

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
23 Sep 2026	5AM Partners VII, LLC 10% owner	Sold at will	$184.91K	100%
23 Sep 2026	Schwab Andrew J. Director	Sold at will	$184.91K	100%
23 Sep 2026	Schwab Andrew J. Director	Sold at will	$7.29K	100%
23 Sep 2026	5AM Partners VII, LLC 10% owner	Sold at will	$7.29K	100%
22 Sep 2026	5AM Partners VII, LLC 10% owner	Sold at will	$45.56K	19.4%
22 Sep 2026	Schwab Andrew J. Director	Sold at will	$45.56K	19.4%

22out of 100

Profitability 5

Financial strength 60

Growth n/a

Insiders 0

Strongest on financial strength (60), weakest on insiders (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$889.20K

18 sales

Planned sales

under a 10b5-1 plan